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Theaccessibilityofskinmakesitanidealtargetorganfornucleicacid-basedtherapeutics;however,effective
patient-friendly delivery remains a major obstacle to clinical utility. A variety of limited and inefficient
methods of delivering nucleic acids to keratinocytes have been demonstrated; further advances will require
well-characterized reagents, rapid noninvasive assays of delivery, and well-developed skin model systems.
Using intravital fluorescence and bioluminescence imaging and a standard set of reporter plasmids we
demonstrate transfection of cells in mouse and human xenograft skin using intradermal injection and two
microneedlearraydeliverysystems.Reportergeneexpressioncouldbedetectedinindividualkeratinocytes,
in real-time, in both mouse skin as well as human skin xenografts. These studies revealed that non-invasive
intravital imaging can be used as a guide for developing gene delivery tools, establishing a benchmark for
comparative testing of nucleic acid skin delivery technologies.
T
he impressive progress in identifying the underlying causes of many epidermal disorders, including geno-
dermatoses, have led to potential therapeutic targets and promising intervention strategies; however, trans-
lation of such novel therapies into the clinic has not been achieved.
1 Nucleic acid-based therapies are strong
candidates for many skin disorders that lack effective treatment options.
2–4 However, realization of this goal will
requirenewmethodsforefficientdeliverythroughthestratumcorneumandefficientuptakeandutilizationofthe
nucleic acid therapeutic by targeted cells. At present, no nucleic acid skin delivery methodologies exist that result
insafeandefficientdeliveryacrossthesebiologicalbarrierswithoutcausingpainortissuedamage.Toaddressthis
need, a consortium of researchers with diverse yet complementary expertise in skin delivery was established
5 to
address the following specific aims: 1. develop and test patient-friendly skin delivery technologies that effectively
and efficiently deliver nucleic acids to skin; 2. combine appropriate and promising technologies to overcome the
delivery barriers and; 3. enable direct comparison of existing delivery technologies through developing, and
making available to the research community, standardized and validated tools, including intravital imaging
systems, mouse and human xenograft skin models and common reagents. Validated reagents and verified skin
models that allow meaningful comparisons are required for effective development of nucleic acid delivery
systems.
Successful development of nucleic acid therapies would clearly benefit from non-invasive imaging modalities
that enable visualization of expression patterns in skin strata in real time. The use of a dual reporter system (e.g.,
expression of luciferase and fluorescent protein from a single plasmid construct) allows for increased data
acquisition since both bioluminescence and fluorescence imaging modalities can be utilized. In vivo biolumin-
escence imaging (BLI)has been shown tobe aversatile and sensitive techniquefor tracking and quantifying gene
expressionandassessingdeliveryefficiency usingreportergenessuchasfireflyluciferase.
6–8Despiteitsstrengths,
BLI has relatively low resolution and therefore detection and identification of individual reporter-positive cells
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offers a complementary approach to BLI for spatiotemporal analysis
of reporter gene expression with the possibility of cellular and sub-
cellular resolution.
9,10 Real-time confocal scanning microscopy has
been adapted to image cells in living tissue and is being applied to
basic research problems, and is finding utility in clinical studies. For
example, confocal reflectance imaging is used to diagnose skin can-
cers, as well as other skin disorders, using intrinsic optical properties
of tissue.
11–15 High-resolution fluorescence microscopes capable of
intravitalskinimaginghavebeendescribed.
6,9,16Forthesestudies,we
chose to use a single axis confocal fluorescence imaging system to
take advantage of its high resolution and real time data acquisition
capabilities.
To test the utility of combining bioluminescence imaging and
fluorescence microscopy to study plasmid delivery and expression
invivo,commonstocksofstandardizeddual-reporter(luciferaseand
GFP) plasmids were evaluated. The plasmids were administered via
intradermal (ID) injection and delivery and expression was com-
pared to that of two different microneedle technologies: soluble pro-
trusion array devices (PADs)
17 and coated metal microneedles.
18,19
Overall plasmid expression was quantified at the tissue level in vivo
usingbioluminescence(luciferase),whichservedasaguideforfluor-
escencemicroscopythatwasusedtolocalizeindividualGFP-positive
cells (keratinocytes) within the luminescent regions of mouse foot-
pad. This combination of technologies and standard reagents estab-
lishes the foundation of an approach for rapidly testing and
validating other nucleic acid delivery technologies.
Results
Dual-mode reporter plasmids enable localization of regions of
gene transfer and allows single keratinocyte detection in mouse
footpad skin. In an effort to standardize gene delivery tools, a series
of expression plasmids utilizing different constitutive human
promoters was prepared and evaluated. These vectors co-express a
modified version of the bioluminescent firefly luciferase enzyme
(luc2, for quantitative analysis) fused to enhanced green
fluorescent protein (eGFP), which allows localization and
characterization of the transfected cells within the epithelium. The
pUbc-luc2/eGFP plasmid (Fig. 1A), which utilizes the human
ubiquitin C (Ubc) promoter, was chosen for further study based
on the strength and uniformity of reporter expression throughout
the various layers of the epidermis (Fig. 1B,C). This construct was
evaluated against pCMV-hMGFP/CBL (Fig. S1A), a construct
previously developed to monitor gene transfer to skin that
expresses click beetle luciferase (CBL) fused to humanized Monster
green fluorescence protein (hMGFP) under the control of the
cytomegalovirus (CMV) promoter.
6,17
The pUbc-luc2/eGFP and pCMV-hMGFP/CBL plasmids were
introduced into mouse footpad skin (left and right, respectively)
via ID injection, and expression levels were imaged 24 h later.
Bioluminescent signals were initially imaged and quantified to loc-
alize regions of interest and guide the fluorescence microscopy.
Although some variability was observed, both constructs expressed
similar levels (n56 mice, p-value50.38) of the reporter (Fig. 1B).
The distribution of pUbc-luc2/eGFP expression through all layers of
the epidermis was confirmed by traditional fluorescence microscopy
of frozen skin sections prepared from treated mice (Fig. 1C). In
contrast, pCMV-hMGFP/CBL expression was confined to the upper
layers (granular and stratum corneum) of the epidermis (Fig. S1), as
previously reported.
6,20–25
FollowingBLI,themicewiththepawsexpressingthehighestlevels
of luciferase were subsequently imaged with a confocal intravital
fluorescence/reflectance Lucid VivaScopeH imaging system. This
desktop confocal scanning laser microscope was initially designed
for reflectance imaging of skin for clinical diagnostic applications
and was recently modified, at our request, to allow fluorescence
imaging via a 488 nm laser (see Materials and Methods). Using this
imaging system, mouse paw skin was initially imaged in the reflec-
tance mode to identify the various skin layers by cell morphology
and tissue structure (see Materials and Methods). Once the desired
layer for analysis was localized, the tissue was scanned using the
488 nm laser (see Fig. 2A for a schematic describing the system’s
capabilities).
After fluorescing cells were detected, a stack (Z-map) of 40 slices
(each 5 mm thick) was obtained, first in fluorescence mode, and then
in reflectance mode, with a separation of 1.6 mm between slices.
Individual cells expressing eGFP in mouse footpad skin were clearly
detected (Fig. 2B,C, left panels). Using the reflectance mode of the
instrument allows discrimination of epidermal layers based on
depth,sizeandgranularity.Granularcellsandcorneocytesarelarger,
irregular and granular (Fig. 2B, right panel) while basal cells and
lower spinous cells are small and regular (Fig. 2C, right panel).
Squame-likeflattenedcellsarevisualizedwhenthetissueisvisualized
from above the epidermis (Fig. 2D, top image) while small and
rounded cells (with basal or spinosum layer characteristics) are
also readily distinguished in a 3D reconstruction rendered from
the Z-stack series (Fig. 2D, bottom image, viewed from below the
epidermis).
Clear differences in pCMV-CBL/hMGFP and pUbc-luc2/eGFP
expression profiles were observed. For example, while eGFP expression
Figure 1 | Detection of reporter plasmid expression in mouse footpad skin. (A) Schematic map of pUbc-luc2/eGFP plasmid. (B) Bioluminescence
imaging of pUbc-luc2/eGFP and pCMV-hMGFP/CBL (left and right paws, respectively) expression 24 h after intradermal paw injection.
(C) Fluorescence microscopy of a skin section obtained from a paw previously imaged for bioluminescence (see Panel B, mouse 3, left paw) injected
with pUbc-luc2/eGFP (scale bar is 50 mm). DAPI stain (blue) was used to identify cellular nuclei. Left panel shows brightfield overlay. Abbreviations:
Ampr, ampicillin resistance; eGFP, enhanced green fluorescence protein; luc2, luciferase 2; Ubc, ubiquitin c; p, photons; sr, steradian.
www.nature.com/scientificreports
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the entire cell (Fig. 1C, 2B and C and Supplemental Video 1), includ-
ing the nucleus, hMGFP expression (from the pCMV-CBL/hMGFP
plasmid), which has been previously shown to form aggregates when
fused with CBL in mouse keratinocytes,
6,9 preferentially accumulated
in the cytoplasm, with little or no nuclear localization (Fig. S1B,
and Supplemental Video 2). Furthermore, the confocal fluorescence
intravital imaging of Ubc promoter-expressed eGFP resulted in a wide
distribution through all layers of the epidermis, including the basal
layer keratinocytes (Fig. 2C and D [bottom] and Supplemental
Video 1), while CMV-mediated expression led to localized hMGFP
expression in the upper (mainly granulosum) layers of the epidermis
(Fig. S1D) and was rarely detectable in deeper layers (Fig. S1 and
Supplemental Video 2). A similar CMV promoter-mediated
Figure 2 | In vivo visualization of eGFP-positive keratinocytes in mouse footpad skin. (A) Schematic representation of the scanning capabilities of the
Lucid VivaScope 2500 intravital imaging system. The scanning dimensions (left panel, top) are 1.231.2 cm. A 433 VivaBlock (right panel, top) is
depictedwithadepthcapabilityof250mm.AsingleVivaBlock(bottompanel)isshownwith10slices(each5mmthick)containinga7503750mmfieldof
view. (B,C) Visualization of individual eGFP-positive cells. In vivo imaging of eGFP-expressing keratinocytes 24 h following ID injection of pUbc-luc2/
eGFPinto mouse footpad skin. Mousepaws were intravitally imaged influorescence (488 nm laser) mode (left panels) at 20.8(B) and 32 (C) mm depths
andtheircorrespondingreflectancemodeimagesareshown(rightpanels).Inreflectance mode(rightpanels),themicroscope allowsvisualization ofcell
morphology and skin layers. Co-localization of cells expressing eGFP (left panels) with skin structure facilitates identification of the keratinocyte
differentiation state.Scalebar is100 mm.(D)3Dreconstructed (40slices) image showingtop(fromstratum corneum) andbottom(fromdermis) views.
Cells are pseudocolored green. SC, stratum corneum. (B–D) Field of view is 7503750 mm.
www.nature.com/scientificreports
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microscopy of skin sections (Fig. 1C and Fig. S1D, respectively), cor-
roborating the intravital imaging results.
VisualizationofeGFP-positivecellsinhumanskinxenografts.For
a predictable and uniform human skin target, we utilized a
commercially available organotypic 3D human skin culture
(StrataTestH, see Materials and Methods). Four weeks after
transplantation of the human skin equivalent onto immuno-
compromised mice, the grafted skin showed little or no evidence of
inflammation and the human epidermis could be readily
distinguished from mouse epidermis by a human keratin 1-specific
antibody (Fig. S2).
To determine if reporter gene expression could be imaged in
human skin xenografts with cellular resolution, the pUbc-luc2/
eGFP plasmid was injected intradermally into transplanted human
skin. After 24 h, the human skin, on live anaesthetized mice, was
imaged by confocal fluorescence microscopy. Individual keratino-
cytes expressing the fluorescence reporter were found at or near the
injection site and Z-stack images were acquired from the top of the
skinto adepth ofapproximately 65mm(seeSupplemental Video3).
EGFP-positive epidermal keratinocytes were clearly visualized
(Fig. 3A) and remained detectable to a depth of approximately 32
mm. The mice were sacrificed 48 h after treatment and the human
skin was removed and cryosectioned for analysis by direct fluor-
escence microscopy and immunostaining. The eGFP-expressing
cells were identified as human keratinocytes by colocalization fol-
lowing immunostaining with a human keratin 1-specific antibody
(Fig. 3C–F).
Plasmid expression following delivery by PAD or coated metal
microneedles to epidermal keratinocytes can be repeatedly
monitored in vivo over time. Once the utility of the imaging
systems and reporter plasmids were validated as outcome
measures, two distinct microneedle designs (coated metal
microneedles and PADs) were utilized. Coated metal microneedles
(Fig. 4A, bottom) or soluble PADs (Fig. 4A, top) of similar
needle lengths (see Fig. 4B and C for side-by-side comparison)
were loaded with plasmid DNA cargo and applied to mouse
footpad skin. Bioluminescent signals from microneedle-delivered
plasmid were monitored over time in live animals. Initially, signals
from tissues treated with both types of microneedle arrays were
similar (Fig. 5A–D). However, while mouse paws treated with
PAD arrays maintained constant reporter gene expression for at
least 24 days (Fig. 5A,B), the paws treated with coated metal
microneedles showed increased bioluminescence during the first
week (Fig. 5C,D) and then reached a higher plateau. In both cases,
metal (Fig. S3, top) and PAD (Fig. S3, bottom), bioluminescent
signals were detected after 72 days following application. Similar
expression, albeit lower (2–6 fold lower expression for metal
coated needles from day 2 until plateau; 2-fold from days 1 to 14
for PADs), was observed following delivery of pCMV-CBL/hMGFP
using both types of microneedle arrays (Fig. S4).
EGFP gene expression in individual epidermal cells following
microneedle application could also be visualized with the confocal
microscope.Pawsexhibitinghighbioluminescentsignals(indicating
functional plasmid delivery) were selected and subjected to confocal
fluorescence imaging. As an example, eGFP-positive cells in mouse
epidermis are shown in Fig. 5E (merged stack of 40 slices) and
Fig. 5G (3D reconstruction) extending from the granulosum [top]
to the basal [bottom] layer, 13 to 64 mm depth, 24 h after applying
PADmicroneedlesloadedwithplasmid.Fluorescencemicroscopyof
frozen skin sections confirmed that eGFP-expressing keratinocytes
were localized in the epidermis of PAD-treated paws (Fig. 5F).
EGFP-expressing cells were also observed following delivery of plas-
mid coated metal microneedles (data not shown). Cells expressing
eGFP were also visualized using the fluorescence imaging system in
human xenografts 24 h following PAD application (Fig. 6A). These
cells are likely keratinocytes based on their morphology and location
as determined using the reflectance mode of the VivaScope imaging
system (Fig. 6B).
Discussion
A plethora of nucleic acid skin delivery technologies have been
described and evaluated by numerous research groups with varying
success. Physical methods include direct hypodermic needle injec-
tion,
6,26,27 electroporation,
28–30 gene gun,
31,32 magnetofection,
33 ionto-
phoresis,
34 radio frequency
35 and microneedle
36,37 applications.
38
Topical formulations that deliver nucleic acids through the stratum
corneum barrier have also been reported.
39–41 In addition, some of
thesemethodsarebeingcombinedwithchemically-modifiednucleic
acids to improve tissue distribution and cellular uptake.
6,17,42,43 These
technologies have been tested in a variety of animal models, organo-
typic skin cultures and skin explants, including those from human.
The 2009 Annual Meeting of the International Pachyonychia
Congenita Consortium (IPCC) focused on issues surrounding effec-
tive delivery of nucleic acids to skin. Although wide-ranging innov-
ative physical and chemical methods were discussed with the goal of
enhancing delivery, it was concluded that there was no existing sys-
tematic way to study and compare the various methods designed to
achieve or enhance delivery.
5 The absence of such validated systems
complicatescomparativeevaluationofmethodsdesignedtoimprove
delivery, which in turn, impedes progress.
The firststep towardscomparativeevaluationofdifferent delivery
technologies was to identify plasmid vectors in which reporter gene
expression in keratinocytes is both strong and uniform throughout
the epidermal layers. Among the promoters traditionally utilized to
express reportergenesinthe skin,CMV isthemost commonlyused,
likely due to its promoter strength and ability to express in a wide
variety of tissue and cell types. However, we confirmed what we and
Figure 3 | Fluorescence microscopic imaging of eGFP reporter plasmid
expression in human skin xenografts. (A) Following ID injection (24 h)
of reporter plasmid (pUbc-luc2/eGFP) into human xenografts (grafted on
immunocompromised mice), individual keratinocytes expressing eGFP
(left panel) are readily observed by intravital microscopy (Lucid system)
using the fluorescence mode at 13 mm depth (the corresponding
reflectancemodeimageisshownintherightpanel).Thescalebaris50mm.
(B) Fluorescence microscopy of frozen sections from skin taken from
previously imaged mice (see panel A), 48 h after injection (scale bar is 20
mm). Brightfield-fluorescence overlay (top left panel). Fluorescence
overlay (top right and bottom panels). eGFP and human keratin 1 are
shown as green and red, respectively. DAPI staining (blue) shows nuclei.
www.nature.com/scientificreports
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dermis is problematic because the majority of expression is found in
the granular and stratum corneum layers
6,20,22,24,25,44,45 (see also Fig.
S1). The reason for this restricted expression pattern is not known,
although several mechanisms have been postulated.
6 Nevertheless,
the asymmetrical expression resulting from the CMV promoter or
CMV enhancer elements complicates side-by-side comparison of
nucleic acid delivery technologies.
As a first step to identify appropriate delivery tools, reporter
expression plasmid constructs were designed and tested to evaluate
their ability to express reporter uniformly throughout the epidermis
with theintent touse thebest performing plasmids toevaluate deliv-
erytechnologies.
6Aluc2/eGFPdualreporterfusionconstruct,driven
by the Ubc promoter was chosen (see Figs. 1 and 2) as it was prev-
iously shown to drive strong detectable reporter gene expression
through all layers of the epidermis, avoiding the non-uniform
expression associated with the CMV promoter as described above.
The reporter luc2 allows for macroscopic in vivo bioluminescence
imaging and in vivo quantification of reporter expression, making
this approach useful forinitial screening of functional plasmid deliv-
ery and localizing regions of interest for further study. Detection of
GFP by in vivo confocal fluorescence microscopy allows for imaging
of tissues at cellular (and even sub-cellular) resolution and local-
ization of GFP-positive keratinocytes in mouse or human skin.
Sub-cellular resolution was observed with the fluorescence
imaging system; nuclei were clearly identified by the absence of
GFP signal (dark region). Interestingly, differential patterns of GFP
cellular distribution were observed for the two fusion proteins uti-
lized. While hMGFP, which was previously shown to form aggre-
gates in the cytoplasm when fused with CBL,
9 is mostly absent from
the nuclei of murine keratinocytes, eGFP tended to uniformly dis-
tribute between cytoplasm and nuclei. This is consistent with a pre-
vious study describing that eGFP, due to its low molecular weight
(27 kDa),diffusesintothenucleiofvariouscelltypes.
46,47Thismech-
anism may involve the ability of proteins less than ,50 kDa (e.g.,
eGFP) to passively transit through the nuclear membrane pores in
the absence of a nuclear localization signal(s).
47,48 It has also been
described that the 50 kDa limit can be exceeded,
47,49 which may
explain why luc2 (,61 kDa) does not impede the diffusion of this
fusion protein into the nuclei of mouse keratinocytes. In contrast,
manyhumankeratinocytesdidnotexhibitnucleareGFP,althoughit
is unclear whether the size or another parameter is responsible for
this differential nuclear localization pattern.
Expression of reporter plasmid was readily observed in human
skin equivalents grafted on immunocompromised mice, suggesting
thissystem maybeusefulfor screening inahuman background. The
xenograftsutilizedinthisstudyconfirmedthatdeliveryoffunctional
reporter plasmid is achievable and readily visualized by in vivo
imaging in human skin (see Figs. 3 and 6). Xenografts were used
as opposed to human skin explants (e.g., from abdominoplasty or
foreskin surgeries) in these studies to take advantage of their uni-
formity, having been made from a cloned, spontaneously immorta-
lized keratinocyte, and that they are commercially available. The
usefulness of human skin xenografts, such as the full thickness skin
equivalents used in this study, may represent an intermediate step,
facilitatingthetranslationofskindeliverymethodologiestopatients.
Despite the efforts of many groups to achieve nucleic acid skin
delivery, only partial progress has been made to effectively translate
these technologies to the clinic.
50,51 For example, intratumoral injec-
tion of plasmid expressing interleukin 2 followed by electroporation
was demonstrated to be safe, effective (resulting in tumor regression
forstageIII/IVmelanomapatients),reproducible,andtitratablewith
transient pain during and after electroporation being the major
adverse event reported.
50 Additionally, an siRNA was successfully
evaluated in a small Phase Ib trial in which the inhibitor was admi-
nistered by ID injection into foot sole lesions of a pachyonychia
congenita (PC) patient.
52 This first-in-skin clinical trial, using a sin-
gle nucleotide, mutation-specific siRNA (TD101, targets a mutant
form of keratin 6a [K6a]), resulted in a positive clinical response
in which the treated skin reverted to ‘‘normal’’ (non-tender) at
the siRNA-treated site, but not the contralateral site injected with
vehicle alone.
52 The mechanism of delivery was likely facilitated by
‘‘pressure-fection’’, based on recently published results showing that
increasing volumes of a fixed amount of intradermally-injected
plasmid led to enhanced delivery of functional nucleic acid.
6
Unfortunately, the intense pain and highly localized delivery assoc-
iated with these intralesional injections preclude future widespread
use in the clinic. Both of these examples resulted in substantial pain
for the patients, underscoring the need for further development of
patient-friendly technologies.
Among the most promising technologies to deliver nucleic acids
(or any cargo that contains large and/or charged molecules) through
the stratum corneum are microneedle patches.
53 The microneedle
protrusions efficiently penetrate the stratum corneum barrier and
are less painful compared to traditional hypodermic needle injec-
tions as they are designed to only penetrate and deliver cargo to the
Figure 4 | Protrusion array device (PAD) and coated metal microneedle arrays. (A) Photographic comparison of PADs and metal microneedle arrays.
PADs containing 335 needles per array (top photograph) are manufactured from polyvinyl alcohol and are designed to dissolve and release cargo when
applied to skin. Metal microneedles (135 needles per array) are coated with cargo to allow rapid delivery to skin following penetration (bottom
photograph). Scale bars 5 1,000 mm. (B) Front (left) and side (right) magnified view of PAD microneedle. Scale bar 5 500 mm. (C) Magnified view of
metal microneedle. Scale bar 5 500 mm.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 158 | DOI: 10.1038/srep00158 5Figure 5 | Intravital imaging of reporter expression in mouse skin following delivery of plasmid by soluble and steel microneedles. One microneedle
arrayloadedwithreporterplasmidwasappliedperpawandsubjectedtoinvivoimaging.Reporterexpression(bioluminescencesignal)wasmonitoredin
vivo over time following administration of pUbc-luc2/eGFP either with PAD (A,B) or steel (C,D) microneedles. Bioluminescent images (A,C) were
generated and the amount of luciferase signal quantified in photons/second/cm
2/steradian and plotted (B,D) Mouse left (LP) and right (RP) paws were
treated (n54) with pUbc-luc2/eGFP and control DNA, respectively. Mouse paws treated with PADs were further in vivo imaged with the VivaScope
confocal microscope, acquiring image stacks from the skin surface to a depth of ,65 mm. (E) En face image of a Z-stack (merge of 40 slices). (F) Frozen
sectionswerepreparedfrompawskinandimagedbytraditionalfluorescencemicroscopyasinFig.1.Scalebaris20mm.(G)3Dreconstructionof40slices
showing top view from stratum corneum (top 3D image) and bottom view from dermis (bottom image). Cells are pseudocolored green.
www.nature.com/scientificreports
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54,55Recentreportshave
demonstrated thatmicroneedles can deliverbothfunctional plasmid
DNA
17,36 and siRNAs.
17
Using BLI initially, we investigated the ability to detect plasmid
delivery using two distinct microneedle designs (see Figs. 4 and 5).
The typical signal intensity (i.e., amount of functional plasmid deliv-
ered) observed was one (for metal coated microneedles) or two (for
PADs)ordersofmagnitudelowerthanachievedbyIDinjectionof20
mgofplasmidasmeasuredbyBLIat24 h(compareFigs.1and6,see
also
6). Increased levels of reporter expression (e.g., 1–2 orders in
magnitude higher than observed in Fig. 1) can be achieved by ID
injection of larger amounts (30–60 mg) of pUbc-luc2/eGFP plasmid
(data not shown). It should be noted that due to limited loading
capacity and the restricted area of the target site (mouse footpad),
microneedle array application results in delivery of much smaller
amountsofplasmidcargo(0.1mgforPADsand3mgformetalcoated
microneedles). In an effort to increase DNA plasmid delivery, mul-
tiple sequential microneedle array applications were attempted, but
no significant improvement was observed (data not shown).
Themechanismof keratinocyteDNA uptakefollowingmicronee-
dle application is not known but may involve cellular membrane
disruption and/or damage caused during microneedle insertion. It
should be noted that microneedle delivery of unmodified siRNA did
not result in detectable target knockdown when applied to mouse
skin in preliminary experiments (data not shown). The use of
siRNAs with so-called self-delivery enhancements (i.e., contain
chemical modifications that enhance cellular uptake) was shown,
however, to result in target reduction.
17 Taken together, these results
suggest that cellular membrane damage or disruption may be
required for plasmid uptake in the absence of pressure or other
delivery agents.
7,17,56
The coated metal microneedles exhibited higher reporter plasmid
expression than PADs, consistent with their higher DNA payload
(i.e., 3 mg for an array of five coated metal microneedles vs. 0.1 mg for
fivePADmicroneedles,seeMaterialsandMethods).Itshouldalsobe
noted that metal microneedles deposit over 80% of their coated
payload within 1 minute when inserted in fresh human skin
57 and
over 90% within 5 minutes when inserted into pig
18 or mouse
58 skin.
Given the extended insertion period used in this study, 20 minutes,
and the high solubility of the DNA cargo in an aqueous milieu, near
complete payload deposition is anticipated. In contrast, PAD micro-
needles have been described to deliver only ,10% of cargo to mouse
skin.
17 Furthermore, the thin structure and increased strength of the
metal microneedles allow for much deeper penetration (up to 700
mm
59). The length, conical shape and skin deformation characteris-
tics of PADs appear to limit penetration to the epidermal and top
dermal layers (about 50–100 mm
17 and data not shown), despite a
similar needle length as the metal microneedles of up to 700 mm.
Although microneedle payload capacity limits its usefulness to
potentmolecules(i.e.,nanogramtomicrogramdoses),thedecreased
pain associated with microneedle delivery systems, coupled with the
ability to directly traverse the stratum corneum barrier, warrants
further development of these technologies.
The standardization and use of molecular tools, nucleic acid
reagents including plasmids, and skin model systems, coupled with
bioluminescence and fluorescence imaging systems as described
herein should allow for direct comparisons of existing and future
nucleic acid delivery technologies. Indeed, this project was funded
by the American Recovery and Reinvestment Act of 2009 (Grand
Opportunity award) with the explicit aim to make these resources
available to the research community to allow comparative testing of
nucleic acid skin delivery methodologies. The identification of the
most promising delivery technologies will allow researchers to focus
efforts on optimization of the most promising approaches with an
eye towards rapid translation to the clinic.
Methods
Animals. 6–8 week old female CD1 (Charles River, Wilmington, MA) and B6.
Cg-Foxn1nu/J mice (The Jackson Laboratory, Bar Harbor, ME) were used according
to procedures approved in animal protocol numbers 10526 and 21627 by the
Administrative Panel for Laboratory Animal Care at Stanford University and animal
protocol number A3230-01 at Yale University, using the guidelines set by the
Institutional Animal Care and Use Committees of the National Institutes of Health,
Stanford University and Yale University.
Plasmids constructions. The pCMV-hMGFP/CBL (clone 138) plasmid was
previously described
9 and contains a fusion of humanized Montastrea cavernosa
(‘‘monster’’) green fluorescence protein (hMGFP) and click beetle luciferase (CBL),
expressed under the control of the cytomegalovirus (CMV) promoter. pUbc-luc2/
eGFPwasgeneratedbyligationoftheUbcpromoterandtheluc2/eGFPcodingregion
of pFULG
60 into the backbone of pCMV-hMGFP/CBL. The 3.7 Kb fragment,
generated from Pac I digestion of pFULG followed by Klenow fill-in to generate a
‘‘blunt end’’ and further digestion with Not I, was ligated into the 3.7 Kb fragment
generated by digestion of pCMV-hMGFP/CBL with Bgl II followed by Klenow fill in
to generate a ‘‘blunt end’’ and further digestion with Not I. All enzymes were
purchased from New England Biolabs (Ipswich, MA).
Microneedle fabrication. Protrusion array devices. PADs were produced as
previously described.
17 Briefly, a template pattern (square grid, 2 mm spacing) of
projecting metal pins was brought into momentary (1 s) contact with a 1 mm thick
film of 20% aqueous polyvinyl alcohol polymer solution supported on a glass
substrate.Thepinswerethenwithdrawnadistanceof1 cmover13 sunderauniform
airflow of 3.0 m/s at 45uC, creating strands of viscous polymer solution, which were
dried in place forming an array of fiber-like protrusions extending from the resulting
drypolymerfilm.Eachfiberstructurecreatedhadaroughlyrectangularbaseofabout
200by500mm,taperingtoafiberwaistwidthofapproximately40mmat1 mmabove
the film surface.
The protrusions were next mechanically separated from the template array with a
razor blade. Each fiber structure was mechanically trimmed with fine scissors at a
nominal 45-degree bevel at approximately 750 mm above the film surface (across the
40mmwaist)toproduceanarrayofsharp,needle-likeprojections(Fig.4A,B).Eachof
these needles was loaded manually from a micropipet tip charged with plasmid
solution (2 mg/ml). The amount of DNA loaded per needle was 0.02 mg based on the
average amount of DNA solution taken up by each needle (10 nl). The dry polymer
needles rapidly imbibe and swell with the charging solution, but retain shape and
sharpnessafterdrying.Subsequenttoloading,PADswerefurtherprocessedina50uC
vacuum oven evacuated to 218 inches mercury pressure for 4 h to dry and ‘‘harden’’
the needle structures to facilitate skin penetration. The integrity of the plasmid DNA
followingPADloadingandprocessingwasconfirmedbyelutingtheplasmidpayload
from microneedle tips (in 50 ml PBS) and analysis by agarose gel 1% (w/v) electro-
phoresis. No differences between PAD-loaded plasmid and the original stock DNA
was observed (data not shown).
Coated metal microneedles. Stainless steel microneedles (,700 mm long, with a base
cross section of 75 by 150 mm) were fabricated using laser cutting and electropol-
ishing, as previously described.
18,59 To apply the plasmid DNA coating solution, the
microneedles were dipped 12 times at 25uC into DNA coating solution (7 mg/ml) in
deionized water using a dip-coatingdevicedescribed previously,
18,59,61 with airdrying
between immersions. Plasmid integrity was confirmed by agarose gel (1% w/v)
electrophoresis after coating and drying procedures by dissolving the DNA on the
microneedles in water (data not shown). Negative control steel microneedles were
coated with salmon sperm DNA (7 mg/ml, Boehringer Mannheim, Penzberg,
Germany). The amount of DNA coated on the microneedle array was determined by
soaking the DNA-coated microneedles in deionized water for 12 h at 4
uC, and the
Figure 6 | Fluorescence imaging of eGFP reporter plasmid expression in
human skin xenografts after PAD application. Following PAD
application (24 h) of reporter plasmid (pUbc-luc2/eGFP) into human
xenografts (grafted on immunocompromised mice), individual
keratinocytes expressing eGFP (left) are observed by intravital microscopy
(VivaScope) using the fluorescence mode at 5–10 mm depth (left). The
corresponding reflectance mode image is shown at the right. Images show
the merge of slices 3 to 6 (of a 40-slice Z-stack). The scale bar is 100 mm.
www.nature.com/scientificreports
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Scientific,Wilmington,DE).TheamountofDNAcoatedwascalculatedtobe3mgper
microneedle array. Each microneedle array consists of 5 single microneedles.
(Fig. 4A,C)
Human skin equivalent xenografts on immunodeficient mice. Human skin
equivalents (StrataTestH) were obtained from StrataTech (Madison, WI). These are
produced in vitro by seeding immortal keratinocytes (NIKSH) on a matrix,
comprisedof humanfibroblastsembedded intype Icollagen.
62Grafting ofStrataTest
skin equivalents was performed under sterile conditions onto the back of B6.
Cg-Foxn1nu/J mice anesthetized by intraperitoneal injection of 100 mg/kg ketamine
(Hospira, Lake Forrest, IL) mixed with 10 mg/kg xylazine (Sigma-Aldrich St Louis,
Mo). Eyes were protected with antibiotic ointment (Vetropolycin, Pharmaderm,
Melville, NY). Prior to surgery, mouse back skin was cleaned with betadine followed
by 70% ethanol.
A square region of mouse back skin (dorsal midline, approximately 1.831.8 cm)
was removed and a 232 cm piece of StrataTest skin equivalent was placed over the
defect, carefully aligning mouse and human skin edges. After waiting five minutes (to
aidadherenceofthegrafttothemouse),thegraftedareawascoveredwithtwolayersof
Vaseline gauze (The Kendall Company, Mansfield, MA), pre-coated with Bacitracin
cream (CVS pharmacy, Woonsocket, RI), a layer of Tegaderm (3 M Health Care,
St. Paul, MN), two bandages (Derma Sciences, Princeton, NJ) covering the size of the
woundandfinallywrappedwithCoban3 Mtape(Andover,Salisbury,MA).Ibuprofen
(Motrin, Upjohn, USA, 0.128 mg/ml) was administered for 48 h in the water.
Following surgery, the mice were monitored daily for the first week and the grafts
wereunbandagedat14days.Miceweretreatednosoonerthantwomonthsfollowing
surgery at which time the grafts had shrunken to about 0.5 cm
2. The presence of
human skin was confirmed by immunofluorescence using human or mouse specific
antibodies as described below and examined by histology stained with Harris
Hematoxylinwithglacialaceticacid,(PloyScientific,BayShore,NY),andEosinY1%
Alcoholic (Poly Scientific) (see Figs. S2 and S3).
Application of microneedle arrays to mouse and human skin. Mouse skin. Four
cohorts of mice (5 mice per group) were treated with metal or PAD microneedles
loaded with plasmid DNA. PAD arrays (335 needles per array), coated with pUbc-
luc2/eGFP (first cohort) or pCMV-hMGFP/CBL (second cohort), were applied by
flicking the array with a finger to seat the needle tips into the left paw followed by
holding the PAD for 1 minute in contact with the skin. Control PADs, loaded with
b-gal expression plasmid DNA (pCMVsport-b-gal, Invitrogen), were applied to the
right paws.
Coated metal microneedle arrays (135 needles per array) coated with pUbc-luc2/
eGFP(third cohort) or pCMV-hMGFP/CBL (fourth cohort) weretightly heldwithin
forceps and inserted in the skin of the left paw by pushing until full penetration was
achieved. As a negative control, the right paw of each mouse was treated with metal
microneedle arrays coated with salmon sperm DNA.
The applied arrays were left seated in the skin for 20 minutes to give the DNA
payloads the opportunity to dissolve inside the skin. After removal, PAD arrays were
observed under an inspection Amscope SM1-BZ microscope (Iscope Corp, Chino,
CA) to assess skin penetration and needle dissolution. Although the footpad is only
large enough to receive about 5 needles simultaneously, the 335 rectangular PAD
needle array served to stabilize and orient the microneedles normal to the footpad
surface. Post-insertion inspection of the array confirmed penetration of ,5 needles
per array per application, as determined by the absence of tip of the needle due to
dissolution upon insertion and removal. Treated paws were analyzed by in vivo
bioluminescence imaging, fluorescence imaging using the VivaScope system or by
traditional microscopy of frozen skin sections as described below.
Human skin equivalents. PAD arrays (535 microneedles) were applied to human
skin equivalents using a vacuum channel plate made from a modified 0.2 mm sterile
syringefilter(Whatman,FlorhamPark,NJ),withonefaceandfilterremoved,leaving
a channeled plate with an exhaust port. Attachment of this exhaust port to a vacuum
pressure station (Bernant Company, Barrington, IL) provided a stable flat surface
with sufficient airflow to hold a PAD over the skin surface. Upon contact with the
plate, the mouse skin was abruptly seated against the channeled plate and the needles
inserted inthe skin.Thevacuumwascontinued for1minuteandthe channeled plate
removed. PADs were left 20 minutes within the skin to allow needle dissolution and
thenremoved.Coatedmetalmicroneedleswereappliedtohumanskinequivalentsin
a similar fashion as described above for mouse paws.
Analysis of reporter expression.
In vivo bioluminescence imaging (BLI). Mice were imaged at the indicated
time points over a 3-month period following microneedle application. D-luciferin
(Biosynth International, Inc., Naperville, IL) was injected (100 ml of a 30 mg/ml
solution; ,150 mg/kg body weight) into the peritoneal cavity of the mice under
isoflurane anesthesia. After 10 min, the live anaesthetized mice were imaged in the
IVIS Spectrum Imaging System (Xenogen product from Caliper LifeSciences,
Alameda, CA) as previously described.
63 The resulting light emission was quantified
using LivingImage software 3.1 (Caliper LifeSciences, Alameda, CA), written as an
overlay on Igor image analysis software (WaveMetrics, Inc; Lake Oswego, Oregon).
The data from six mice were statistically analyzed using a paired T-test.
Fluorescence imaging. Plasmids (20 mg of pUbc-luc2/eGFP or pCMV-hMGFP
in 100 ml PBS) were intradermally injected or applied via microneedle arrays as
describedabovetofootpadsofanesthetized(2–3%isoflurane)CD1mice.
64Micewere
anesthetized 24 hours later with isoflurane and GFP reporter expression in paws was
imaged using the Lucid VivaScope 2500 System (Lucid Inc., Rochester, NY).
9,10
AquasonicH100(Parkerlaboratories,INC.Fairfield,NJ)ultrasoundtransmissiongel
wasusedasimmersionmediumbetweentheobjectivelensandthetissuecassette.The
mouse paw to be imaged was placed over the glass window of the tissue cassette after
adding Crodamol
TM STS (Croda Inc., Edison, NJ) as index matching fluid (index of
refraction51.47).TheZ-depthpositionwasadjustedbyidentifyingthesurfaceofthe
tissue using the 630 nm reflectance laser.
Using this same laser, the position in the skin (e.g. stratum corneum, granulosum,
spinal layer, basal layer, etc.) was identified.
65 After switching to the 488 nm fluor-
escence excitation laser, Vivablocks (XY position map) were used to screen the tissue
to locate GFP-positive cells (the signal displays as white colored over a black back-
ground) at this selected depth. Once cells expressing eGFP or hMGFP were found,
Vivastack(Z-axis map)imageswereobtained,firstinfluorescence mode,andthenin
reflectance mode (40 slices with a Z separation of 1.6 mm between slices [5 mm thick],
see Fig. S4 for details on VivaScope settings when scanning skin tissue). The field of
view was 7503750 mm and the images were collected at 9 frames per second. Image
files were processed and 3D volumes and video files were reconstructed using ImageJ
(National Institutes of Health, Bethesda, MD).
Skin sectioning and immunofluorescence.Followingfluorescenceimaging,
intradermally-injected and microneedle-treated mice were sacrificed. Skin tissues
were removed from the footpad, embedded in O.C.T. compound (Tissue-TekH,
Torrance, CA) and frozen in dry ice. Vertical cross sections (10 mm) were obtained
using a microtome and mounted with Hydromount
TM (National Diagnostic,
Highland Park, NJ) containing 49,6-diamidino-2-phenylindole (DAPI, 1 mg/ml,
Sigma) for nuclear staining. Tissue sections were imaged by fluorescence microscopy
as previously described
9.
Human skin xenografts were harvested 48 h following injection of pUbc-luc2/
eGFP. Cryosections were fixed with acetone/methanol at 220 degrees for 10 min,
washed in PBS and incubated at room temperature with 10% goat serum/1% BSA/
0.025% Triton X-100 in PBS for 1 h, followed by incubation with primary antibody
(e.g. mouse or human keratin 1 [Covance, Emeryville, CA]) in 10% goat serum/1%
BSATriton X-100(inPBS)for 1 hatroomtemperature. After washingwithPBS, the
skin sections were incubated with secondary antibody (goat anti-rabbit Cy3,
Covance) in 10% goat serum/1% BSA/0.025% Triton X-100 for 1 h at room tem-
perature. Nuclei were stained with DAPI for 3 minutes, and washed again in PBS,
mounted and stored in the dark. Images were acquired with a ZEISS Axiovert 200
microscope (Carl Zeiss, Inc., Thornwood, NY).
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